Moreover, monoclonal antibodies targeting EGFR and its downstream signaling pathways were reported in treating colorectal cancer, head and neck carcinomas, but few reports comprehensively investigated the clinical outcomes in NSCLC (94). This evidence concerns the gene EGFR and head and neck carcinoma.